For a payer covering millions of lives with drug spend in the billions, the cost of a comprehensive commercial platform is trivial relative to the budget at risk
(Extended reading: After Tirzepatide's approval for the treatment of obesity, how long will it be before Eli Lilly's small molecule GLP-1R agonist becomes available?) Volenrelaxin (LY3540378) is a long-acting synthetic relaxin analogue that acts as an agonist for the relaxin family peptide receptor 1 (RXFP1), developed by Eli Lilly for the treatment of chronic heart failure
Microinjection of a SP receptor antagonist into the amygdala was anxiolytic, where SP was anxiogenic (Ebner et al., 2004
In the case of GLP-1s, this is largely due to a lack of knowledge about their effects
This is also seen in medications for depression (SSRIs), which increase serotonin to help regulate mood and are known to cause low libido and delayed/anorgasmia as well
10.1161/01.HYP.0000251162.14782.d4 188